Zürcher Nachrichten - DR Congo drug manufacturing plan sparks safety concerns

EUR -
AED 4.242869
AFN 76.250342
ALL 93.247528
AMD 421.964016
AOA 1060.572233
ARS 1728.626236
AUD 1.637747
AWG 2.082442
AZN 1.95442
BAM 1.95517
BBD 2.323451
BDT 142.793982
BHD 0.43505
BIF 3442.245991
BMD 1.155308
BND 1.479204
BOB 14.010485
BRL 5.937698
BSD 1.153603
BTN 109.671657
BWP 15.643552
BYN 3.4119
BYR 22644.030618
BZD 2.320142
CAD 1.618476
CDF 2612.150446
CHF 0.931709
CLF 0.026743
CLP 1055.974029
CNY 7.798053
CNH 7.795213
COP 3676.986215
CRC 523.120097
CUC 1.155308
CUP 30.615654
CVE 110.229477
CZK 24.187288
DJF 205.419355
DKK 7.475378
DOP 67.276572
DZD 153.581966
EGP 57.556847
ERN 17.329615
ETB 186.190862
FJD 2.553806
FKP 0.858651
GBP 0.857925
GEL 3.021126
GGP 0.858651
GHS 13.525641
GIP 0.858651
GMD 84.914239
GNF 10132.383874
GTQ 8.799164
GYD 241.32223
HKD 9.061864
HNL 30.919233
HRK 7.533413
HTG 150.826824
HUF 362.202869
IDR 20696.181862
ILS 3.470255
IMP 0.858651
INR 109.822567
IQD 1511.219527
IRR 1588317.004451
ISK 141.80247
JEP 0.858651
JMD 183.31537
JOD 0.819133
JPY 182.194907
KES 149.462068
KGS 101.031383
KHR 4675.351658
KMF 493.31666
KRW 1638.053175
KWD 0.357244
KYD 0.961394
KZT 541.347885
LAK 26077.708924
LBP 103304.008718
LKR 387.05831
LRD 208.222897
LSL 18.925383
LTL 3.411323
LVL 0.698834
LYD 7.342475
MAD 10.751835
MDL 20.043627
MGA 4910.290079
MKD 61.505179
MMK 2425.340128
MNT 4157.025473
MOP 9.319937
MRU 46.258492
MUR 54.264829
MVR 17.849421
MWK 2000.294776
MXN 19.917441
MYR 4.722435
MZN 73.836264
NAD 18.925383
NGN 1572.905055
NIO 42.454848
NOK 11.010256
NPR 175.469896
NZD 1.961395
OMR 0.444221
PAB 1.153628
PEN 3.905142
PGK 5.172176
PHP 70.03013
PKR 320.314956
PLN 4.300516
PYG 6879.634064
QAR 4.217541
RON 5.244867
RSD 117.359633
RUB 93.554303
RWF 1694.602551
SAR 4.335326
SBD 9.321425
SCR 15.49527
SDG 693.766315
SEK 10.9609
SGD 1.47936
SLE 28.429167
SOS 659.267569
SRD 43.518143
STD 23912.536514
STN 24.491365
SVC 10.093791
SZL 18.909415
THB 38.2141
TJS 10.647669
TMT 4.043577
TND 3.384909
TRY 54.983998
TTD 7.824327
TWD 37.250007
TZS 3061.563041
UAH 51.622323
UGX 4302.613418
USD 1.155308
UYU 46.385052
UZS 13713.580591
VES 871.346053
VND 30308.341798
VUV 138.133218
WST 3.161791
XAF 655.725817
XAG 0.018555
XAU 0.00027
XCD 3.122277
XCG 2.079039
XDR 0.815516
XOF 655.731491
XPF 119.331742
YER 273.663498
ZAR 18.861902
ZMK 10399.156062
ZMW 22.021903
ZWL 372.008603
  • CMSC

    -0.0600

    21.73

    -0.28%

  • CMSD

    0.0200

    22.04

    +0.09%

  • NGG

    -0.1600

    80.26

    -0.2%

  • BTI

    0.1500

    59.27

    +0.25%

  • RBGPF

    0.0000

    69.74

    0%

  • BCE

    0.0600

    22.06

    +0.27%

  • RIO

    2.5000

    101.51

    +2.46%

  • AZN

    5.8800

    161.5

    +3.64%

  • RELX

    -0.1900

    36.61

    -0.52%

  • GSK

    -0.0700

    51.46

    -0.14%

  • RYCEF

    0.6000

    21

    +2.86%

  • BCC

    -1.6900

    84.8

    -1.99%

  • JRI

    -0.0500

    12.67

    -0.39%

  • VOD

    -0.3800

    15.31

    -2.48%

  • BP

    -1.2300

    41.21

    -2.98%

DR Congo drug manufacturing plan sparks safety concerns
DR Congo drug manufacturing plan sparks safety concerns / Photo: Barbara DEBOUT - AFP

DR Congo drug manufacturing plan sparks safety concerns

Sitting at his desk overlooking a pharmaceutical factory floor on the outskirts of the Congolese capital Kinshasa, Joss Ilunga Dijimba, 52, cracked a jovial smile.

Text size:

"It's not easy doing business in Congo," he said.

His family was forced to relocate the factory in the 1990s to survive bouts of mass looting. And nowadays, there are onerous taxes, customs duties, and problems retaining talented staff.

His company, which employs about 40 people and produces generics such as paracetamol, is one of a tiny number of drug manufacturers in the Democratic Republic of Congo, an impoverished nation roughly the size of Western Europe.

But a government plan to require hospitals and NGOs to buy more locally produced drugs could soon boost the fledgling pharmaceutical industry -- despite fears in some quarters that safety standards are far below international norms.

Several NGOs, some of which provide medical care in the DRC's conflict-torn east, have requested opt-outs.

At the small Pharmagros plant, behind barbed-wire walls near the Congo river, men in hairnets and white coats formulate medicines with imported precursor using lab equipment in airconditioned rooms.

"Promoting local industry's a good thing," said Dijimba, a University of Texas graduate, insisting that several Congolese firms, including his, maintained high standards.

"It could grow the middle class."

About 73 percent of the DRC's population of 90 million lives on under $1.9 a day, according to the World Bank. Most products in the African country are imported.

- 'At your own peril' -

The Congolese government has designated 35 drug molecules, including paracetamol, that medical facilities will be required to purchase in locally made form.

The government wants to stimulate business without banning imports, said Donatien Kabamb Kabey, the pharmaceuticals director at the DRC's health ministry.

He explained that all the molecules can be replaced with imported equivalents, suggesting that ibuprofen could replace paracetamol, for example.

Although not yet implemented, the policy already appears to be working.

Fifteen new pharma businesses are setting up in the DRC ahead of the new rules, Kabey said, which will add to the existing 24.

The policy was partly designed to encourage factories to return after fleeing the country in the 1990s, he added, when unpaid soldiers went on the rampage towards the end of ex-dictator Mobutu Sese Seko's reign.

But experts warn that Congolese-made medicines face a major challenge: reassuring doctors and patients that they meet regulatory standards.

"When you go to the private sector in Congo, you do it at your own peril," said Ed Vreeke, who runs the Belgium-based independent pharmaceutical auditing firm Quamed.

"They know darn well that the quality they produce is not good."

Vreeke said Congolese regulators had improved, but the country lacked the massive resources needed to properly perform audits, check labels, and inspect the chemical composition of drugs for safety.

Kabey, whose department at the health ministry oversees inspections, said standards had improved "enormously" in recent years, but did not provide further details.

He said the government was establishing a national quality-control lab.

- 'A huge thing' -

Shoddy or falsified medicines kill hundreds of thousands of people every year, according to the World Health Organization, mostly in poor countries.

The DRC's hot and humid climate also poses storage problems.

A 2021 study of both imported and locally produced eye drops sold in Kinshasa, for example, showed that three out of the seven products tested were substandard. The one sample manufactured in the DRC was contaminated.

Outside a pharmacy in Kinshasa's upmarket Gombe district, clutching a bag of medicines, 29-year-old corporate lawyer Joelle Mamputu said she didn't pay attention to where drugs were made but said she had "no prejudice".

However, a 52-year-old public servant named Olivier said there was "quite a difference" between Congolese and foreign drugs.

He added he would buy Congolese drugs were the quality the same.

Despite official assurances, major international NGOs such as Doctors Without Borders (MSF) and Medecins du Monde (MDM) have requested opt-outs from the purchasing requirements, several humanitarian workers said.

MSF declined to comment.

MDM confirmed it had asked for an exemption due to concerns over quality and capacity to meet demand.

"It's a huge thing," said one humanitarian who asked for anonymity, explaining that the new rules will affect all non-governmental organisations, hospitals and pharmacies.

Many aid workers understand the need to promote enterprise, he said, but there are internal disagreements about whether to compromise on quality.

"We need to have high quality standards for everyone, but the reality of the country is that sometimes it's impossible".

L.Rossi--NZN